aBLA Filing Intelligence & Biosimilar Opportunity

Nemluvio

Nemolizumab-Ilto

Immunomodulators

Prefilled Pen For Injection

Nemluvio is an injectable antibody for adults suffering from debilitating itch in prurigo nodularis or moderate-to-severe atopic dermatitis. It blocks the IL‑31 receptor to reduce itching and improve skin healing, offering relief within 48 hours.

Approval Date

12-Aug-24

Data Exclusivity Expiry

12-Aug-28

Market Exclusivity Expiry

12-Aug-36

Commercial snapshot

Market performance & projections

Revenue ($M)

452

CAGR (%)

0.5788

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

1115

2027

1671

2028

2265

2029

2808

2030

3279

2031

3743

2032

4191

Molecule profile

Details & specifications

Molecule

Nemolizumab-Ilto

Innovator

CHUGAI PHARMACEUTICAL CO., LTD.

Dosage Form

Prefilled Pen For Injection

Strength

30 mg

Therapeutic Category

Immunomodulators

Usage

To treat prurigo nodularis

Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.